Press Releases
2012
Kane Biotech Renews Investor Relations Agreement
With Pure Advertising and Marketing for 2012
January 17, 2012
2011
Kane Biotech submits Supplemental Data on KBI Disinfectant to Health Canada
December 15, 2011
Kane Biotech Announces Appointment of Mark Matthewson as New CFO
December 12, 2011
Kane Biotech Issued New Patents in China and USA
December 8, 2011
Kane Biotech Announces Extension of Term of Warrants
November 11, 2011
FDA Provides Feedback and Roadmap for DispersinB® Development
November 9, 2011
Kane Biotech Receives Approval from Health Canada for Hard Surface Disinfectant
October 12, 2011
Kane Biotech Files New Patent on Bone Tissue Regeneration Invention
August 30, 2011
DispersinB® Effective Against Superbug MRSA
July 26, 2011
Kane Biotech Appoints Interim CFO and Announces Grant of Options
July 14, 2011
Kane Biotech submits DispersinB® wound spray briefing document to the FDA
July 7, 2011
Kane Biotech Announces New Board Members
June 29, 2011
Kane Biotech Awarded Contract by the United States Army to Develop Antibiofilm-Antimicrobial Wound Gel
May 31, 2011
Kane Biotech Announces Changes to the Board of Directors
May 6, 2011
Kane Biotech Announces Closing of Private Placement Offering
April 15, 2011
Kane Biotech Announces Increase to Private Placement Offering
April 6, 2011
Kane Biotech Announces Private Placement Offering
March 30, 2011
Kane Biotech Named One of World's Top Ten "Most Innovative Companies" in Biotech by Fast Company Magazine
February 24, 2011
Kane Biotech Issued Additional Patent on Biofilm Technology
February 8, 2011
Kane Biotech Sells First Set of DispersinB® ELISA Kits to MIT, University of Toronto and University of Washington
February 1, 2011
DispersinB® Wound Spray Passes Final Biocompatibility Sub-Chronic Toxicity Test
January 26 , 2011
Kane Biotech Announces Grant of Options
January 19 , 2011
Kane Biotech Retains Pure Advertising & Marketing for Investor Relations
January 13 , 2011